Met-HeFTHot Line 6Heart Failure

Evaluating Metformin Therapy in Patients With Chronic Heart Failure

Metformin in patients with chronic heart failure

Presenting authorHenrik WiggersHeart Failure / Cardiomyopathy · Aarhus University

Henrik Wiggers is a Clinical Professor at Aarhus University, Department of Clinical Medicine, and a consultant in the Department of Cardiology at Aarhus University Hospital. He was appointed clinical professor of heart failure in 2019. His research focuses on the failing heart in diabetes, prediabetes and cardiac valve disease, using positron emission tomography, invasive hemodynamics and hyperpolarized MR, and he has led the nationwide DANHEART study.

Overview

Pending metformin trial in chronic HF leaves efficacy unresolved; randomized results needed before any practice consideration.

Key result

Metformin in patients with chronic heart failure is the subject of a late-breaking trial at ESC Congress 2026, for which results are currently pending.

Discussion

Expert reaction lands here the moment Met-HeFT reports.

Expert takes

Met-HeFT is a Danish multicenter, randomized, double-blind, placebo-controlled trial evaluating metformin versus placebo in patients with chronic HFrEF (LVEF ≤40%) who have type 2 diabetes, prediabetes, or insulin resistance. It is part of the DANHEART 2×2 factorial design and is the largest randomized trial to date of metformin in patients with established heart failure, with results to be presented by Henrik Wiggers at ESC Congress 2026 Hot Line 6. No verifiable expert quotes about the trial's results or significance were found in the source material.

Tomasz Guzik

Chair, ESC Congress Program Committee

“Randomized controlled trials are the cornerstone of evidence-based cardiovascular medicine because they provide the highest level of evidence to guide clinical practice. This year, ESC Congress received a record number of submissions of late-breaking clinical trials, reflecting the remarkable pace of innovation across cardiology. We rigorously selected the studies with the greatest scientific quality and potential clinical impact.”

European Society of Cardiology

Key Points

Evaluation of metformin in patients with chronic heart failure investigates therapeutic outcomes within a late-breaking clinical session.
Presented findings at ESC Congress 2026 evaluate metformin treatment effects in chronic heart failure cohorts with results currently pending.
Clinical trial presentation highlights metformin administration across chronic heart failure cases to clarify long-term cardiovascular impact.

Main Result

Absolute Event Rate: 0% vs 0%

AIに質問

Bookmark

View Full Paper